Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

6.93
+0.10001.46%
Post-market: 6.90-0.0300-0.43%19:50 EDT
Volume:6.04M
Turnover:42.23M
Market Cap:2.43B
PE:-15.80
High:7.09
Open:6.98
Low:6.88
Close:6.83
52wk High:9.75
52wk Low:2.76
Shares:351.12M
Float Shares:264.00M
Volume Ratio:0.72
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4387
EPS(LYR):-0.6000
ROE:-47.81%
ROA:-12.36%
PB:9.58
PE(LYR):-11.55

Loading ...

Nuvation Bio announces annual shareholder meeting via webcast

Reuters
·
Apr 10

Nuvation Bio Chief Regulatory Officer Kerry Wentworth disposes 200,000 shares for $903,560

Reuters
·
Apr 09

RBC Capital Sticks to Their Buy Rating for Nuvation Bio (NUVB)

TIPRANKS
·
Apr 08

JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB)

TIPRANKS
·
Apr 07

RBC Raises Price Target on Nuvation Bio to $20 From $13, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Apr 06

Nuvation Bio Inc : RBC Raises Target Price to $20 From $13

THOMSON REUTERS
·
Apr 06

U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio

Reuters
·
Apr 06

Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?

Simply Wall St.
·
Apr 04

Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Apr 02

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Apr 02

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

MT Newswires Live
·
Apr 01

Nuvation Bio acquires Japan rights to safusidenib from Daiichi Sankyo

Reuters
·
Apr 01

Nuvation Bio Inc - Buys Japan Rights to Safusidenib From Daiichi Sankyo

THOMSON REUTERS
·
Apr 01

Nuvation Bio Inc - Gains Ownership of Global Clinical Development Program for Safusidenib

THOMSON REUTERS
·
Apr 01

Nuvation Bio (NUVB) Receives a Buy from Wedbush

TIPRANKS
·
Mar 27

Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Mar 27

March 2026's Promising Penny Stocks To Watch

Simply Wall St.
·
Mar 27

Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe

TIPRANKS
·
Mar 27

Nuvation Bio shares rise; EMA validates taletrectinib MAA for advanced ROS1+ NSCLC in Europe

Reuters
·
Mar 27

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

THOMSON REUTERS
·
Mar 27